ICH Adds More Q&As
This article was originally published in The Gold Sheet
The ICH Quality Implementation Group in October added several questions and answers to its guide for helping manufacturers implement its Q8, Q9 and Q10 guidelines. One of the additional questions is: "What is an appropriate approach for process validation using ICH Q8, Q9 and Q10?" The answer: "the objectives of process validation are unchanged when using ICH Q8, Q9 and Q10. The main objective of process validation remains that a process design yields a product meeting its pre-defined quality criteria…As an alternative to the traditional process validation, continuous process verification can be utilized in process validation protocols for the initial commercial production and for manufacturing process changes for the continual improvement throughout the remainder of the product lifecycle." ICH also addressed the role of risk management and continuous process verification in continuous improvement, clarified that parametric release is a type of real-time release, and explained that under QbD, even with real-time release testing, the product would still have to meet traditional specifications if subjected to end product testing. The agency also clarified that under Q10, some elements of the control strategy are subject to inspection
You may also be interested in...
The ICH Quality Implementation Working Group has developed a question-and-answer guide to help manufacturers implement its Q8, Q9 and Q10 guidelines. The Q&A has three QbD topics: design space, real-time release testing, and control strategy. ICH announced that "the benefits of harmonizing technical requirements across the ICH regions can only be reached if the various Q-ICH guidelines are implemented and interpreted in a consistent way across the three regions." The document was approved by the ICH Steering Committee as a Step 4 document on April 14
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.
But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.